Archives

by in
Entry Author Date Location
West Coast Biotech Roundup: Seragon, Ambrx, Pregenen, and More 07/03/14 San Diego
As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund 06/10/14 San Francisco
OncoGenex Retrenches, and Searches for Answers, After Failed Trial 05/22/14 Seattle
OncoGenex’s Long Wait For Cancer Drug Ends With a Phase 3 Stumble 04/28/14 Seattle
What Biotech Pros Will Be Chirping About at JP Morgan This Week 01/13/14 National
3 Life Sciences Companies That Are Built to Last 12/02/13 National
Dendreon Cuts 150 Jobs, As Prostate Cancer Drug Sales Decline 11/12/13 Seattle
Arno, With Potential Suitor in Opko, Goes After Endometrial Cancer 11/06/13 New York
Dendreon Says Sales Will Decline in 2013, Shares Fall 08/08/13 Seattle
San Diego Life Sciences Roundup: Aragon, Santarus, Tocagen, and More 06/20/13 San Diego
IMS Health Acquires Appature to Get Healthcare Marketing Software 03/12/13 Seattle
Prostate Cancer Drug Winners and Losers at ASCO GU 02/15/13 National
Tokai Looks to Follow Fast Behind J&J, Medivation in Prostate Cancer 02/13/13 Boston
Poll: Which of These 10 New Drugs Is Priced Too High? 02/11/13 National
Crowdfunding Is Coming to Biotech, so Get Ready for a Wild Ride 01/28/13 National
Who Are Biotech’s New Go-To Investment Bankers? 11/12/12 National
Betting on Biotech to Catalyze U.S. Job Growth? Don’t Count On It 10/01/12 National
Fearless Football and Biotech Picks For Fall 2012 09/04/12 National
Medivation Wins FDA Approval of Prostate Cancer Drug 08/31/12 San Francisco
Alzheimer’s R&D Isn’t Doomed, it’s Learning From Failure 08/20/12 National
OncoGenex Waits, and Waits, For Data on Prostate Cancer Drug 08/02/12 Seattle
Dendreon Cutting 600 Jobs, Closing NJ Plant As Sales Fall Short 07/30/12 Seattle
The Best Boring Companies in Biotech 07/09/12 National
Emerging Challenges of Prostate Cancer Drug Development 06/06/12 National
ASCO Wrap-Up: A Summary of This Week’s Cancer R&D Headlines 06/05/12 National
Medivation Emerges With New Prostate Cancer Drug 05/31/12 San Francisco
Dendreon’s Provenge Works Best for Patients With Low PSA, Scientists Say 05/16/12 Seattle
ASCO Preview: Eight Cancer Drugs to Watch at the Big Show 05/14/12 National
Dendreon CEO John Johnson: ‘This is My Last Stop’ 04/17/12 Seattle
OncoGenex Snags $50M for Prostate Cancer Drug Plan 03/16/12 Seattle
Page 1 of 2 next page »